Safety and efficacy of a high-intensity, weight-based, intravenous heparin protocol revision in patients who are obese

Hospital Pharmacy

Volumn 43, Issue 11, 2008, Pages 895-902

  Dee, Brian M ^a   Thomas, Michael L ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b TOLEDO HOSPITAL   (United States)

Author keywords

Heparin; Obesity; Weight based

Indexed keywords

HEPARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY WEIGHT; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBESITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY;

EID: 57149110669     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4311-895     Document Type: Article

References (15)

1. Fahey VA. Heparin-induced thrombocytopenia. J Vasc Nurs. 1995;13(4): 112-116.
2. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol. 2000;12 (suppl F):14F-19F.
3. Kakkasseril JS, Cranley JJ, Panke T, Grannan K. Heparin-induced thrombocytopenia: a prospective study of 142 patients. J Vasc Surg. 1985;2(3):382-384.
4. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993;119(9):874-881.
5. Centers for Disease Control and Prevention. Overweight and Obesity: Obesity Trends: US Obesity Trends 1985-2007. www.cdc.gov/nccdphp/dnpa/ obesity/trend/maps/index.htm. Accessed October 2, 2008.
6. Centers for Disease Control and Prevention. Overweight and Obesity: Obesity Trends: Prevalence of Overweight and Obesity Among Adults: United States, 1999-2002. http://wvvw.cdc.gov/nchs/products/pubs/pubd/hestats/ obese/obse99.htm. Accessed September 11, 2006.
7. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm. 1998;55(2):159-162.
8. Schaefer DC, Hufnagle J, Williams L. Rapid heparin anticoagulation: use of a weight-based nomogram. Am Fam Physician. 1996:54(8):2517-2521.
9. Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health Syst Pharm. 2001;58(22):2143-2146.
10. Schwiesow SJ, Wessell AM, Steyer T. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother. 2005;39(4): 753-756.
11. Khan SU, Groth ML, Hurewitz AN. Optimal dosing of unfractionated heparin in obese patients with venous thromboembolism. Chest. 2005;128(4): 406S-407S.
12. Sheth H, Bonner J, Skledar S, et al. Failure of heparin dosing guidelines in obese patients: time for reevaluation. Chest. 2005;128(4):193S.
13. Barletta J, DeYoung JL, McAllen K, et al. The impact of obesity on the effect of intravenous heparin using a standardized dosing nomogram [abstract]. Crit Care Med. 2006;34:A149.
14. Holliday DM, Watling SM, Yanos J. Heparin dosing in the morbidly obese patient. Ann Pharmacother. 1994;28(9): 1110-1111.
15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.